Tonix is developing innovative pharmaceutical products to address major public health challenges. In addition to Tonmya for PTSD, Tonix is developing TNX-601 (tianeptine oxalate), a clinical candidate at pre-IND (Investigational New Drug) application stage, designed as a daytime treatment for PTSD, and TNX-801, a live synthetic version of horsepox virus, at the pre-IND application stage, to be developed as a potential smallpox-preventing vaccine.

Pharmaceutical

Tonix Pharmaceuticals

Seth Lederman

Gary Brune

Ram Patalapati

Jean Engels

Scott Szymanski

Sina Bavari

Darryl Rideout

Bradley Saenger

Jessica Edgar Morris

Gregory Sullivan

Siobhan Fogarty

The Research and Development team at Tonix Pharmaceuticals is responsible for advancing the company's innovative pharmaceutical products from concept to clinical development. This includes conducting in vitro studies, developing and producing antibodies, managing clinical programs, analyzing intellectual property, ensuring quality assurance, planning and conducting biostatistical analysis, and overseeing analytical development. Their work supports the development of candidates like TNX-601 for PTSD and TNX-801 for smallpox prevention.

Research and Development

Leadership Team

Clinical Operations Team

Research and Development

About

Team members

Other teams at Tonix Pharmaceuticals

Leadership Team

Clinical Operations Team